What Eli Lilly, Novo Nordisk earnings reveal about the future of GLP-1 sales

  • 📰 YahooFinanceCA
  • ⏱ Reading Time:
  • 29 sec. here
  • 8 min. at publisher
  • 📊 Quality Score:
  • News: 36%
  • Publisher: 63%

Novo Nordisk News

Eli Lilly,Weight Loss,Weight-Loss Drug

GLP-1s continue to fuel investor interest in market competition, as companies prepare to differentiate themselves in the coming year.

missed second quarter Wall Street estimatesfor its GLP-1 sales. It beat Wall Street quarterly sales projections by 13% — with total sales of $4.3 billion for weight-loss drug Zepbound and diabetes drug Mounjaro. The stock surged more than 10% on Thursday as a result of Lilly signaling the easing of supply constraints helped Novo too. Its stock rose 5% that day.

Which is why some say market moves based on quarterly results in the near term isn't a good strategy. PARIS — Three German swimmers became ill after competing in the open water races at the Paris Olympics, though it was not immediately clear if the long-polluted Seine River was responsible for their sickness.

Jimmy Fallon has worked with Steph Curry before, so maybe it was easy for the superstar who delivered an all-timer of a performance for Olympic gold to pose for the Tonight Show host in the middle of a game. Because that's exactly what happened.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 47. in UK
 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

United Kingdom United Kingdom Latest News, United Kingdom United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Excitement grows around Eli Lilly's GLP-1 drugs in Q2 earningsShares of Eli Lilly (LLY) are jumping after the company posted second quarter earnings results, beating expectations on both the top and bottom lines. The...
Source: YahooFinanceCA - 🏆 47. / 63 Read more »

What Eli Lilly, Novo Nordisk earnings show about GLP-1 salesRecent earnings from Eli Lilly and Company (LLY) and Novo Nordisk (NVO) highlight the demand for GLP-1 drugs and why not all GLP-1 providers may be created...
Source: YahooFinanceCA - 🏆 47. / 63 Read more »